Context Therapeutics (CNTX) AI Stock Analysis

• Market Cap: $217.75M
• Dividend Yield: N/A
• Average Volume (3M): 1.97M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 69.30%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 91,879,170
• 10 Day Avg. Volume: 3,070,991
• 30 Day Avg. Volume: 1,973,408
• PEG Ratio: 0.03
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -36.93K
• Enterprise Value/Ebitda: -5.13
• 1Y Price Target: $5.67
• Price Target Upside: 139.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $2.50 ▲(5.49% Upside)

The score is primarily held back by weak financial performance (no revenue, ongoing losses, and cash burn), partially offset by a strong technical uptrend. Valuation is limited by negative earnings (negative P/E), while the recent pipeline update and stated runway provide some supportive momentum but remain execution-dependent.

Positive Factors

Pipeline Focus: T‑cell Engagers

A concentrated R&D focus on bispecific T‑cell engagers (three distinct programs) creates a clear strategic roadmap and scientific differentiation. Targeting large solid tumor antigens with selectivity and lower cytokine risk improves long‑term commercial potential if clinical proofs occur, aiding partnership interest.

Very Low Leverage

Minimal debt provides structural financial flexibility for a clinical‑stage biotech, reducing fixed creditor pressure and enabling prioritization of R&D spend. Low leverage improves ability to negotiate partnerships or equity raises on better terms and lengthens optionality to fund trials over the medium term.

Stated Cash Runway and Milestones

A disclosed runway into 2027 coupled with scheduled Phase 1a data, dose selection, and FIH plans allows management to execute multiple de‑risking milestones before near‑term financing is required. This timeline supports value creation opportunities and potential partner or non‑dilutive funding discussions.

Negative Factors

Pre‑revenue with Material Net Losses

Being pre‑revenue means the business lacks recurring commercial cash flows and relies on financing to progress programs. Sustained net losses erode equity and limit self‑funding capacity, increasing dependency on external capital and amplifying dilution risk for existing shareholders over the medium term.

Negative Operating and Free Cash Flow

Ongoing cash burn at this scale necessitates future capital raises or partnerships to complete clinical development. Persistent negative FCF constrains long‑term program execution, may force capacity tradeoffs, and creates execution risk if market conditions or partner interest tighten when funding is needed.

Clinical Execution and Data Dependency

Progress and valuation hinge on binary clinical outcomes across early‑stage trials; failed or delayed data can materially impair program value and financing access. This structural development risk is typical for clinical biotechs and can prolong timelines or require partnering, affecting long‑term upside.

Context Therapeutics Business Overview & Revenue Model

Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Context Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships and collaborations with other pharmaceutical firms to advance its clinical trials and bring its therapies to market. Revenue is generated through milestone payments, licensing agreements, and potential future sales of approved drugs. Additionally, Context Therapeutics may receive funding through government grants and private investments to support its research and development activities.

Context Therapeutics Financial Statement Overview

Summary

Very low leverage supports financial flexibility, but the company remains pre-revenue with sizable operating/net losses and meaningfully negative operating and free cash flow, implying ongoing funding needs and continued pressure on equity.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and a sizable net loss (~$26.4M), with operating losses remaining heavy (EBIT ~-$30.2M). Losses have generally widened versus 2022–2023, indicating a cost base that is not yet supported by commercial revenue. A modest positive is that net loss in TTM is roughly in line with 2024, suggesting burn is not accelerating sharply year-over-year, but profitability remains weak and highly dependent on future funding and pipeline progress.

Balance Sheet

Leverage is very low (TTM debt-to-equity ~0.002), giving the company financial flexibility and limiting balance-sheet risk from creditors. However, equity has declined from 2024 to TTM (about $95.3M to $73.2M), consistent with ongoing losses and/or capital structure changes, and returns on equity are negative (TTM ROE about -39%). Overall, the balance sheet looks conservatively financed, but it is being pressured by continued losses.

Cash Flow

Cash generation remains negative, with TTM operating cash flow around -$22.3M and free cash flow around -$22.4M, reflecting continued cash burn typical of a pre-revenue biotech. A key positive is that free cash flow improved versus 2024 (positive free-cash-flow growth in TTM), but cash flow is still meaningfully negative and will likely require ongoing capital raises or partnership funding if revenues do not materialize.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.07K	0.00	0.00	0.00	0.00	0.00
EBITDA	-29.28M	-29.91M	-25.06M	-14.87M	-10.39M	-2.57M
Net Income	-26.44M	-26.73M	-23.96M	-14.84M	-10.46M	6.64M
Balance Sheet
Total Assets	79.23M	98.13M	16.06M	37.97M	51.31M	467.34K
Cash, Cash Equivalents and Short-Term Investments	76.94M	94.43M	14.45M	35.50M	49.64M	341.04K
Total Debt	140.20K	219.38K	0.00	55.08K	0.00	5.95M
Total Liabilities	6.06M	2.86M	4.19M	3.21M	3.03M	17.39M
Stockholders Equity	73.17M	95.27M	11.87M	34.76M	48.27M	-16.92M
Cash Flow
Free Cash Flow	-22.38M	-29.31M	-21.05M	-14.09M	-9.05M	-1.03M
Operating Cash Flow	-22.35M	-14.56M	-21.05M	-13.55M	-8.80M	-1.03M
Investing Cash Flow	-33.95K	-14.76M	0.00	-536.84K	-250.00K	0.00
Financing Cash Flow	14.52M	109.29M	0.00	-102.07K	58.39M	1.15M

Context Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Positive. The current price of 2.37 is above the 20-day moving average (MA) of 1.87, above the 50-day MA of 1.44, and above the 200-day MA of 1.02, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 73.58 is Negative, neither overbought nor oversold. The STOCH value of 72.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTX.

Context Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CNTX	57 Neutral	$217.75M	-8.82	-33.68%	―	―	69.30%
WHWK	56 Neutral	$135.73M	21.21	-13.82%	―	-42.62%	―
ADAG	53 Neutral	$138.57M	-4.58	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QNCX	40 Underperform	$10.02M	-0.12	-247.78%	―	―	2.26%
ANEB	40 Underperform	$39.33M	-4.04	-145.11%	―	―	23.10%

Context Therapeutics Corporate Events

Context Therapeutics Highlights T Cell Engager Pipeline Strategy

On January 8, 2026, Context Therapeutics updated its corporate presentation to outline its strategy of building a leading pipeline of T cell engager therapies for solid tumors, highlighting three main bispecific antibody programs—CTIM-76 (Claudin 6 x CD3), CT-95 (mesothelin x CD3), and CT-202 (Nectin-4 x CD3)—each designed for highly selective tumor targeting and reduced cytokine release risk in large oncology indications. The company reported a strong financial position with an expected cash runway into 2027 and detailed upcoming development milestones, including updated Phase 1a data and dose selection for CTIM-76 in the second quarter of 2026, initial Phase 1a data for CT-95 in mid-2026, and regulatory filings to begin first-in-human trials for CT-202 in the second quarter of 2026, positioning Context to compete in a growing TCE market that has already seen multiple successful commercial launches in both solid and liquid tumors.

The most recent analyst rating on (CNTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.

Context Therapeutics Reports Q3 2025 Financial Results

On November 5, 2025, Context Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical trials. The company is progressing with its CTIM-76 and CT-95 trials, showing promising safety profiles and preliminary anti-tumor activity in early phases. The company plans to continue dose escalation and expects to release further data in 2026, which could impact its market positioning and stakeholder interests.

The most recent analyst rating on (CNTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.